1-800-710-4674

News Releases

Return to News

Breaking News from OHC

 
OHC-ASCO-Annual-Meeting-2016

OHC Physicians Share Advances in Lung and Pancreatic Cancer Research at ASCO Annual Meeting

OHC, Blogs, News Releases, 2 comments
July 19, 2016

 

OHC’s David M. Waterhouse, MD, MPH, and Patrick Ward, MD, Ph.D., recently presented findings from clinical trials for non-small cell lung and metastatic pancreatic cancer patients at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

“This year’s ASCO annual meeting focused on the importance of combined knowledge from various disciplines, cancer types, treatment approaches, and big data technologies all focusing on advances in cancer care,” said Dr. Waterhouse, chair of the OHC Research Department. “As the region’s only oncology medical home and leader in clinical trials, we are proud to have been a part of this year’s conference and making a difference in the lives of our patients by providing access to high-quality clinical research and groundbreaking advancements in cancer treatment.”

OHC’s presentations at ASCO included:

  • The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer. (Abstract 9092)
  • The Rainier clinical trial: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract 4119)
  • Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study. (Abstract 5053)
  • Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153. (Abstract 3059)

OHC had one of the largest clinical trial enrollments for a new drug to fight lung cancer, anti–PD-1 agent Nivolumab (Opdivo). The drug was approved three months ahead of the FDA’s scheduled decision date.

“I believe patients should be offered leading edge care and given every opportunity to participate in their care decisions with the guidance and support from their medical team,” said Dr. Patrick Ward. “Through the clinical trials offered at OHC, our patients are offered treatment options not yet available to the public along with standard of care protocols to help them manage their cancer.”

The OHC Research Program currently participates in many early drug development research trials, which provides innovative, leading-edge options for patients. We were recognized in 2015 as one of six community oncology programs in the country by the Conquer Cancer Foundation for the American Society of Clinical Oncology (ASCO) for its commitment to high-quality clinical trial programs.

To learn more about OHC’s clinical trial menu, visit our research section.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *

2 Responses

  1. JP Heiremans says:

    OHC has certainly made a believer out of me, I owe them my life!